Perry E K, Pickering A T, Wang W W, Houghton P, Perry N S
Medical Research Council, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom.
J Altern Complement Med. 1998 Winter;4(4):419-28. doi: 10.1089/acm.1998.4.419.
The use of complementary medicines such as plant extracts in dementia therapy, varies according to the different cultural traditions. In orthodox Western medicine, contrasting with that in China and the Far East for example, pharmacological properties of traditional cognitive or memory enhancing plants have not been widely investigated in the context of current models of Alzheimer's disease. An exception is Ginkgo biloba in which the ginkgolides have antioxidant, neuroprotective, and cholinergic activities relevant to Alzheimer's disease mechanisms. The therapeutic efficacy of Ginkgo biloba extracts in Alzheimer's disease in placebo-controlled clinical trials is reportedly similar to currently prescribed drugs such as tacrine or donepezil and, importantly, undesirable side effects of Ginkgo biloba are minimal. Old European reference books (eg, medical herbals) document a variety of other plants such as Salvia officinalis (sage) and Melissa officinalis (balm) with memory improving properties, and cholinergic activities have recently been identified in extracts of these plants. Precedents for modern discovery of clinically relevant pharmacological activities in plants with long-established medicinal use include, for example, the interaction of alkaloid opioids in Papaver somniferum (Opium poppy) with endogenous opiate receptors in the brain. With recent major advances in understanding the neurobiology of Alzheimer's disease, and as yet limited efficacy of so-called rationally designed therapies, it may be timely to re-explore historical archives for new directions in drug development. This article considers not only the value of an integrative traditional and modern scientific approach to developing new treatments for dementia, but also in the understanding of disease mechanisms. Long before the current biologically based hypothesis of cholinergic derangement in Alzheimer's disease emerged, plants now known to contain cholinergic antagonists were recorded for their amnesic and dementia-inducing properties.
在痴呆症治疗中,植物提取物等补充药物的使用因不同文化传统而有所差异。例如,在正统西医中,与中国和远东地区不同,传统认知或增强记忆植物的药理特性在当前阿尔茨海默病模型背景下尚未得到广泛研究。银杏是个例外,其中银杏内酯具有与阿尔茨海默病机制相关的抗氧化、神经保护和胆碱能活性。据报道,在安慰剂对照临床试验中,银杏叶提取物治疗阿尔茨海默病的疗效与目前处方药物如他克林或多奈哌齐相似,重要的是,银杏叶的不良副作用极小。古老的欧洲参考书(如医学草药)记载了多种其他具有改善记忆特性的植物,如鼠尾草和蜜蜂花,最近在这些植物的提取物中发现了胆碱能活性。在长期用于药用的植物中发现临床相关药理活性的现代先例包括,例如,罂粟中的生物碱阿片类物质与大脑中的内源性阿片受体相互作用。随着最近在理解阿尔茨海默病神经生物学方面取得的重大进展,以及所谓合理设计疗法的疗效仍然有限,重新探索历史档案以寻找药物开发的新方向可能恰逢其时。本文不仅考虑了传统与现代科学相结合的方法在开发痴呆症新疗法方面的价值,也考虑了在理解疾病机制方面的价值。早在当前基于生物学的阿尔茨海默病胆碱能紊乱假说出现之前,现在已知含有胆碱能拮抗剂的植物就因其失忆和诱发痴呆的特性而被记载。